Technicals Stability Returns

TopStockResearch Live Pattern Finder Plan Starts @ Rs 991/year
  •   Pattern Screener
  •   Potential Pattern
  •   Time Machine
  •   TSR Plan
Fundamental Analysis of Aurobindo Pharma (AUROPHARMA)

Summary    Balance Sheet    Cash Flow    Income    Qtrly Income    Valuation Ratio    Profitability Ratios    Solvency    Efficiency Ratios    

Guru Numbers
Book Value/Share419.38
EV/EBITDA8.21
Market Cap (Cr)33319.42
Enterprise Value (Cr)31502.18
Piotroski F-Score7.00
Altman Z Score4.48
Graham No653.12
Price/ Graham 0.871
Peter Lynch Ratio-4.00
Sloan Ratio0.0249
Peter Lynch Fair value228.09
Price/ Peter Lynch FV2.49
TSR Fair value1606.06
Key Financial ratios of AUROPHARMA
Ratio Latest FY Yoy Change TTM MRQ Screener/
About
Price to Earning    14.79 52.84 % 12.58    
Price to Book    1.59 -32.30 % 1.44 1.36    
Price to Sales    1.67 -20.57 % 1.42    
Earning Per Share    45.19 -50.37 % 45.21 9.84    
Return On Equity    10.78 -55.71 % 11.49 2.35    
Return On Asset    7.81 -50.46 % 7.80 1.70    
Net Profit Margin    11.29 -48.03 % 11.32 9.92    
Operating Profit Margin    13.35 -26.74 % 13.39 9.61    
EBITDA Margin    19.39 -43.71 % 19.44 14.74    
Debt to Equity Ratio    0.097 -59.93 % 0.097    
Current Ratio    2.22 19.55 % 2.22    
Quick Ratio    1.30 28.00 % 1.30    
View Historitcal ratios of Aurobindo Pharma Ltd.
Valuation Ratios   Profitability Ratio   Solvency Ratios   Efficiency Ratios
Screen Financial Ratio using Custom Screener
Terrific View
Tsr Stability Index - Excellent Score of 90.62
Piotroski F Score - Good Value of 7.0
Altman Z Score of 4.48 suggests good Stability
Undervalued - Price to Intrinsic Value of 0.354
Price to Earning Ratio is 12.58 and EV to EBITDA is 6.93 suggesting company is undervalued.
Earning Yield of 7.95 %
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Tremendous increasing in Book Value last 3 year
Steady View
Steady increase in Total Assets for last 3 Years
Company financial liquidity has improved
Good Return on Equity of 11.49% is achieved by the company
Good Net Margin of 11.32% is achieved by the company
Risky View
Tsr Growth Index - Poor Score of 24.58
Tsr Profitability Index - Poor Score of 23.75
Stock Returns < -44.15 % Than Nifty in last one year
Stock Returns is less than Nifty returns for consequitive last three years
EPS decline for last four quarters
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned51.80 %
Institution Owned38.30 %
Public/Others9.90 %
Outstanding Shares58.59 Cr
Floating Shares17.69 Cr
Floating / Outstanding30.18%
Book Value/Share419.38
Face value1.00
Share Holding
Annual Key Income Statement of AUROPHARMA
Period 31_Mar_2022 31_Mar_2021 Growth
Net Income From Continuing Ops 2647.11 5333.83 50.37 %
Net Income 2648.15 5334.84 50.36 %
Operating Income 3132.28 4476.41 30.03 %
Total Revenue 23455.49 24557.94 4.49 %
Operating Expense 20106.30 10179.06 97.53 %
Interest Expense 48.64 59.57 18.35 %
Tax Expense 725.63 2009.77 63.89 %
Income Before tax 3372.74 7343.59 54.07 %
Gross Profit 13315.21 14655.47 9.15 %
Dividend Paid -263.70 -234.31 12.54 %
   
Quarterly Key Income Statement of AUROPHARMA
Period 31_Mar_2022 31_Dec_2021 Growth
Net Income From Continuing Ops 576.14 604.29 4.66 %
Net Income 576.46 604.73 4.67 %
Operating Income 558.07 752.01 25.79 %
Total Revenue 5809.37 6002.22 3.21 %
Operating Expense 5074.51 5272.21 3.75 %
Interest Expense 9.21 16.13 42.90 %
Tax Expense 17.49 189.49 90.77 %
Income Before tax 593.63 793.78 25.21 %
Gross Profit 3285.17 3257.98 0.835 %
Dividend Paid -263.70 0 %
   
Key Balance Sheet Fields
Period 31_Mar_2022 31-Mar-21 Growth
Common Stock 58.59 58.59 0 %
Current Liabilities 8155.98 10665.15 23.53 %
Total Liabilities 9345.74 11925.00 21.63 %
Current Assets 18122.69 19823.51 8.58 %
Total Assets 33921.72 33853.99 0.200 %
Working capital 9966.71 9158.36 8.83 %
Accounts Payable 2703.05 2794.68 3.28 %
Inventory 7553.85 9026.57 16.32 %
Net Receivable 4386.90 4015.46 9.25 %
   
Key Cash Flow Fields
Period 31_Mar_2022 31_Mar_2021 Growth
Cash EPS 63.67 109.04 41.61 %
Cash From Investment Activity -3211.56 598.69 636.43 %
Cash From Financial Activity -2969.27 -1364.81 117.56 %
Cash Operational Activity 5016.48 3328.92 50.69 %
Net Cash Flow -1164.35 2562.80 145.43 %
NetIncome 2648.15 5334.84 50.36 %
Capital Expenditure 2052.91 1873.81 9.56 %
Change To Inventory 1497.52 -1593.58 193.97 %
   



   About Aurobindo Pharma Limited
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Address : Galaxy, Plot No. 1, Hyderabad, India, 500032

URL : https://www.aurobindo.com

Employee Count : 15431

About TSR TECH Strength / Valuation / Growth

TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick

TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential

TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value

This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback

We are working on fundamental strength also. Please share your views to help shape up the requirement.